Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 0.00% is 100% below its 5-year average of 15.09%, near the high end of its 5-year range (-656700.00%–92.19%).
As of the fiscal period ended Tuesday, June 30, 2026.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 0.00%.
GROSS MARGIN
0.00%
GROSS MARGIN AVG TTM
0.00%
GROSS MARGIN AVG 3Y
0.00%
GROSS MARGIN AVG 5Y
15.09%
GROSS MARGIN AVG 10Y
-19.35%
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
-100.00%
CURRENT VS 10Y AVG
+100.00%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
42.91%
median of 588 covered companies
CURRENT VS SECTOR MEDIAN
-100.00%
vs the sector median at left
Inhibikase Therapeutics, Inc.
Market Cap
$261.43M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
15.09%
Market Cap
$259.91M
Gross Margin
93.41%
TTM Avg
92.41%
3Y Avg
88.66%
5Y Avg
85.93%
Market Cap
$264.16M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$256.98M
Gross Margin
100.00%
TTM Avg
-14.56%
3Y Avg
-49.51%
5Y Avg
-80.59%
Market Cap
$255.89M
Gross Margin
62.16%
TTM Avg
59.97%
3Y Avg
63.15%
5Y Avg
60.27%
Market Cap
$255.42M
Gross Margin
88.00%
TTM Avg
94.00%
3Y Avg
97.00%
5Y Avg
64.67%
Market Cap
$272.17M
Gross Margin
-94.12%
TTM Avg
-431.85%
3Y Avg
-231.35%
5Y Avg
-189.25%
Market Cap
$250.09M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
25.00%
5Y Avg
50.00%
Market Cap
$274.61M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Inhibikase Therapeutics, Inc. (IKT) | $261.43M | 0.00% | 0.00% | 0.00% | 15.09% |
| EyePoint Pharmaceuticals, Inc. (EYPT)vs › | $259.91M | 93.41% | 92.41% | 88.66% | 85.93% |
| Eupraxia Pharmaceuticals Inc. (EPRX)vs › | $264.16M | 0.00% | 0.00% | 0.00% | 0.00% |
| AC Immune S.A. (ACIU)vs › | $256.98M | 100.00% | -14.56% | -49.51% | -80.59% |
| Anika Therapeutics, Inc. (ANIK)vs › | $255.89M | 62.16% | 59.97% | 63.15% | 60.27% |
| Century Therapeutics, Inc. (IPSC)vs › | $255.42M | 88.00% | 94.00% | 97.00% | 64.67% |
| Fate Therapeutics, Inc. (FATE)vs › | $272.17M | -94.12% | -431.85% | -231.35% | -189.25% |
| Lexeo Therapeutics, Inc. Common Stock (LXEO)vs › | $250.09M | 0.00% | 0.00% | 25.00% | 50.00% |
| Indaptus Therapeutics, Inc. (INDP)vs › | $274.61M | 0.00% | 0.00% | 0.00% | 0.00% |
| Aurora Cannabis Inc. (ACB)vs › | $276.57M | 42.62% | 48.63% | 38.13% | 25.55% |
Gross Margin
0.0%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 0.00% |
| 2026-03-31 | 0.00% |
| 2025-12-31 | 0.00% |
| 2025-09-30 | 0.00% |
| 2025-06-30 | 0.00% |
| 2025-03-31 | 0.00% |
| 2024-12-31 | 0.00% |
| 2024-09-30 | 0.00% |
| 2024-06-30 | 0.00% |
| 2024-03-31 | 0.00% |
| 2023-12-31 | -656700.00% |
| 2023-09-30 | 91.75% |
| 2023-06-30 | -36.76% |
| 2023-03-31 | 92.19% |
| 2022-12-31 | 92.07% |
| 2022-09-30 | 76.94% |
| 2022-06-30 | -45415.61% |
| 2022-03-31 | -6454.26% |
| 2021-12-31 | -174295.99% |
| 2021-09-30 | -860.41% |
| 2021-06-30 | -74.79% |
| 2021-03-31 | -72.82% |
| 2020-12-31 | -33.17% |
| 2020-09-30 | -219.98% |
| 2020-06-30 | -19.85% |
| 2020-03-31 | -4.55% |
| 2019-12-31 | -11.50% |
| 2019-09-30 | -104.91% |
| 2019-06-30 | -183.98% |
| 2019-03-31 | -163.20% |
| 2018-12-31 | 0.00% |
| 2018-03-31 | 15.32% |
| 2017-12-31 | 0.00% |
| 2017-03-31 | -3.85% |
